An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients
Marine Rousset(Université de Bordeaux), Mathiéu Molimard(Université de Bordeaux), Mireille Canal‐Raffin(Université de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Karine Titier(Centre Hospitalier Universitaire de Bordeaux), Stéphane Bouchet(Université de Bordeaux), Anne Pham‐Ledard(Peter MacCallum Cancer Centre), S. Prey(Centre Hospitalier Universitaire de Bordeaux)
Cited by 33
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k